Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE CLINICAL USE OF PLASMA CLOZAPINE LEVELS
Autore:
BELL R; MCLAREN A; GALANOS J; COPOLOV D;
Indirizzi:
MENTAL HLTH RES INST,LOCKED BAG 2 PARKVILLE VIC 3052 AUSTRALIA
Titolo Testata:
Australian and New Zealand Journal of Psychiatry
fascicolo: 4, volume: 32, anno: 1998,
pagine: 567 - 574
SICI:
0004-8674(1998)32:4<567:TCUOPC>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERFORMANCE LIQUID-CHROMATOGRAPHY; REFRACTORY SCHIZOPHRENIC-PATIENTS; NEUROLEPTIC MALIGNANT SYNDROME; ULTRAVIOLET DETECTION; N-DESMETHYLCLOZAPINE; SERUM CONCENTRATIONS; MAJOR METABOLITES; PHARMACOKINETICS; CARBAMAZEPINE; PHARMACODYNAMICS;
Keywords:
CLINICAL RESPONSE; CLOZAPINE; PLASMA LEVEL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Citazioni:
54
Recensione:
Indirizzi per estratti:
Citazione:
R. Bell et al., "THE CLINICAL USE OF PLASMA CLOZAPINE LEVELS", Australian and New Zealand Journal of Psychiatry, 32(4), 1998, pp. 567-574

Abstract

Objective: This review examines the evidence supporting the proposition that a threshold clozapine plasma level can predict clinical response. In addition, it provides a brief overview of the pharmacokinetics,side effects, drug interactions and assay methodology of clozapine. Method: A comprehensive search of relevant literature was made with respect to the above criteria. The findings were collated and analysed toproduce an overview of the usefulness of using clozapine levels in clinical practice. Results: Most researchers find that, although the correlation between dose of clozapine and clinical effect is not high, a threshold plasma level of 350-420 ng ml(-1) of clozapine is associatedwith an increased probability of a good clinical response to the drug. Results vary, however, with the study design. Conclusions: The data reviewed present a case for increasing the dose of clozapine in non-responsive patients to achieve a plasma level of at least 350-420 ng mL(-1). Non-response at these levels, however, should not preclude a further upward titration of dose. This should occur unless (i) clinical response is obtained at a lower dose, (ii) intolerable side effects occur, or (iii) a daily dose of 900 mg is reached.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 14:53:25